Report topline data for the TMB-001 Phase 2B trial
Delivered after the deadline (7 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- 7 Oct 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data for Phase 2B trial”
What we found
Evidence strength A What the grades mean
The company announced the topline data for the TMB-001 Phase 2b trial on October 7, 2021, which occurred after the Q3 2021 deadline.
-
A Timber Pharmaceuticals, Inc. 10-Q filed 2021-11-15
“On October 7, 2021, we announced top line data from the TMB-001 Phase 2b trial.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- TMB-001 Phase 2B topline data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Timber Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C504167-023121 · Corrections policy